Balchem Corporation Signs Definitive Agreement to Acquire Kappa Bioscience AS
Posted: June 14, 2022
June 14, 2022
Balchem Corporation has signed a definitive agreement to acquire Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway.
Ted Harris, Chairman, CEO and President of Balchem said, “We are thrilled to welcome Kappa Bioscience’s strong and experienced team to Balchem. This acquisition accelerates our strategy to expand our portfolio of science-based specialty nutrients with leading positions in growing markets.”
